Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-09 |
2024-03 |
-0.18 |
-0.16 |
0.02 |
11.11% |
2024-02-28 |
2023-12 |
-0.2 |
-0.16 |
0.04 |
20.00% |
2023-11-07 |
2023-09 |
-0.31 |
-0.35 |
-0.04 |
-12.90% |
2023-08-08 |
2023-06 |
-0.39 |
-0.47 |
-0.08 |
-20.51% |
2023-05-09 |
2023-03 |
-0.41 |
-0.52 |
-0.11 |
-26.83% |
2023-02-28 |
2022-12 |
-0.47 |
-0.44 |
0.03 |
6.38% |
Date |
Firm |
Action |
From |
To |
2023-08-07 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-08-07 |
Credit Suisse |
Upgrade |
Outperform |
Outperform |
2023-08-07 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
2023-08-06 |
Needham |
Upgrade |
|
Buy |
2023-07-30 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-07-27 |
Citigroup |
Downgrade |
Buy |
Neutral |
Date |
Name |
Relation |
Quantity |
Description |
2024-01-15 |
BALA MOHAN |
Officer |
14.05K |
Sale |
2024-01-15 |
CARVAJAL ALEJANDRA V. |
Officer |
27.40K |
Sale |
2024-01-01 |
DERE WILLARD H |
Director |
39.18K |
Stock Award(Grant) |
2024-01-15 |
DESCHUYTNER BRIAN |
Chief Operating Officer |
54.51K |
Sale |
2023-06-07 |
HEGE KRISTEN |
Director |
14.47K |
Stock Award(Grant) |
2024-01-15 |
LOWINGER TIMOTHY B |
Chief Technology Officer |
199.33K |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Bain Capital Life Sciences Investors, LLC |
8.66M |
28.50M |
7.19% |
2023-06-29 |
Blackrock Inc. |
7.96M |
26.20M |
6.61% |
2023-06-29 |
Orbimed Advisors LLC. |
7.21M |
23.74M |
5.99% |
2023-06-29 |
Avoro Capital Advisors LLC |
6.38M |
20.97M |
5.29% |
2023-06-29 |
Vanguard Group Inc |
5.72M |
18.83M |
4.75% |
2023-06-29 |
Bellevue Group AG |
5.22M |
17.17M |
4.33% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
3.41M |
11.23M |
2.83% |
2023-08-30 |
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF |
2.84M |
3.15M |
2.35% |
2023-08-30 |
iShares Russell 2000 ETF |
2.26M |
2.50M |
1.87% |
2023-06-29 |
Vanguard Extended Market Index Fund |
1.49M |
4.91M |
1.24% |
2023-07-30 |
TIAA-CREF Funds-Quant Small Cap Equity Fund |
1.04M |
1.27M |
0.86% |
2023-07-30 |
Fidelity Small Cap Index Fund |
884.27K |
1.08M |
0.73% |